FGFR
Fibroblast growth factor receptor
FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.
All Product Categories
-
FGFR Inhibitors
(317)
View all products
-
FGFR Agonists
(4)
View all products
-
FGFR Antagonist
(1)
View all products
-
FGFR Activators
(5)
View all products
-
FGFR Modulators
(3)
View all products
-
FGFR Degraders
(11)
View all products
-
FGFR Control
(1)
View all products
-
FGFR Ligand
(1)
View all products
-
FGFR Proteins
(97)
View all products
-
FGFR-1 Proteins
(20)
View all products
-
FGFR-2 Proteins
(31)
View all products
-
FGFR-3 Proteins
(26)
View all products
-
FGFR-4 Proteins
(18)
View all products
-
FGFR Related Products (383)
Related Products (383)
-
Recombinant Proteins (97)
-
Antibodies (11)
-
Ponatinib-d8
0 ImagesSynonyms: AP24534-d8
-
Erdafitinib (Standard)
0 ImagesSynonyms: JNJ-42756493 (Standard)Erdafitinib (Standard) is the analytical standard of Erdafitinib. This product is intended for research and analytical applications. Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
-
Nintedanib (Standard)
0 ImagesSynonyms: BIBF 1120 (Standard)Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
MD-3-A45
0 ImagesMD-3-A45 is an inhibitor of fibroblast growth factor 23 (FGF-23). MD-3-A45 blocks the activation of the FGFRs/α-klotho signaling pathway by FGF-23 and inhibits FGF-23-induced ERK activation. MD-3-A45 can be used in the research of chronic kidney disease, hereditary hypophosphatemic rickets and acquired hypophosphatemic rickets.
-
HuGAL-FR21
0 ImagesCat. No.: HY-P991584HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer.
-
Dovitinib lactate hydrate
0 ImagesCat. No.: HY-B0062CAS No.: 915769-50-5Synonyms: TKI258 lactate hydrate; CHIR-258 lactate hydrate
-
Regorafenib mesylate
0 ImagesCat. No.: HY-10331BCAS No.: 835621-08-4Synonyms: BAY 73-4506 mesylateRegorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity.
-
Segigratinib
0 ImagesCat. No.: HY-159503CAS No.: 1882873-93-9Synonyms: 3D185 free base; HH185 free baseSegigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect.
-
S49076 hydrochloride
0 ImagesCat. No.: HY-12965ACAS No.: 1265966-31-1S49076 hydrochloride is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
-
MAX-40279 hydrochloride
0 ImagesCat. No.: HY-145723ACAS No.: 2388506-51-0MAX-40279 hydrochloride is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hydrochloride inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hydrochloride can be used for the research of acute myelogenous leukemia (AML).
-
MAX-40279 hemifumarate
0 ImagesMAX-40279 hemifumarate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemifumarate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemifumarate can be used for the research of acute myelogenous leukemia (AML).
-
E7090 succinate
0 ImagesE7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.
-
FGFR4-IN-11
0 ImagesCat. No.: HY-147515CAS No.: 2396664-85-8FGFR4-IN-11 (Compound 30) is a potent, selective, covalent FGFR4 inhibitor with an IC50 of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity.
-
FGFR4-IN-4
0 ImagesCat. No.: HY-129181CAS No.: 2230973-67-6FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1.
-
PHM16
0 ImagesCat. No.: HY-117595CAS No.: 1448791-29-4PHM16 is an ATP competitive inhibitor of FAK and FGFR2 (IC50: 0.4 μM and 0.37 μM, respectively), with direct potent anti-angiogenic activity.
-
FIIN-4
0 ImagesCat. No.: HY-123134CAS No.: 2093088-81-2FIIN-4 is a first-in-class, orally active and covalent FGFR inhibitor with IC50s of 2.6 nM, 2.6 nM, 5.6 nM, 9.2 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FIIN-4 can inhibit metastatic tumor growth.
-
FGFR4-IN-14
0 ImagesCat. No.: HY-155046CAS No.: 3027827-02-4FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC50: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC50s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC).
-
FGFR2 K659M Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70818FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659M is a mutant of FGFR3. FGFR2 K659M Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659M protein that can be used to study FGFR2 K659M-related functions.
-
FGFR1 inhibitor-2
0 ImagesCat. No.: HY-139376CAS No.: 2410612-08-5FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.
